Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas - PubMed (original) (raw)
. 2000 Mar 1;60(5):1383-7.
Affiliations
- PMID: 10728703
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas
L Frederick et al. Cancer Res. 2000.
Abstract
Several types of epidermal growth factor receptor (EGFR) gene mutations have been reported in glioblastomas, and in nearly all cases the alterations have been reported in tumors with EGFR amplification. The objectives of this study were to determine the frequency and diversity of EGFR mutations in glioblastomas and to determine whether gene mutation is inevitably associated with increased EGFR gene dosage. To accomplish these aims, we sequenced cDNA products representing the entire EGFR coding region in 44 glioblastomas, half of which had EGFR amplification. Coding sequence alterations were identified in 17 of the tumors, and each of these cases had amplified EGFR. No mutations were identified in the 22 tumors without EGFR amplification. An additional 26 glioblastomas with EGFR amplification were then examined to establish more reliable frequencies for each type of mutation identified in the tumors for which the entire gene was sequenced. Transcripts associated with the most common mutation lacked coding sequence for amino acids 6-273 (67%). This mutation has been described extensively in the literature. Transcripts encoding receptors that would truncate at amino acid 958 and transcripts encoding receptors that would lack amino acids 521-603 were the next most common types of alteration. Each of these were observed in 15% of the tumors with EGFR amplification. Other mutations were observed at lower frequencies, but among these were three cases with missense mutations. Sixteen of the 48 tumors with EGFR amplification showed multiple types of EGFR mutations (33%), and in one case it was determined that multiple alterations had occurred in the same transcript. In total, these data are consistent with EGFR mutation being exclusively and frequently associated with EGFR amplification. Furthermore, the determination of multiple EGFR mutations within individual tumors suggests that glioblastomas with EGFR amplification have the capacity to produce a variety of functionally distinct EGFRs.
Similar articles
- Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FG 2nd. Aghi M, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8600-5. doi: 10.1158/1078-0432.CCR-05-0713. Clin Cancer Res. 2005. PMID: 16361543 - Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.
Idbaih A, Aimard J, Boisselier B, Marie Y, Paris S, Crinière E, Carvalho Silva R, Laigle-Donadey F, Rousseau A, Mokhtari K, Thillet J, Sanson M, Hoang-Xuan K, Delattre JY. Idbaih A, et al. Neuropathol Appl Neurobiol. 2009 Apr;35(2):208-13. doi: 10.1111/j.1365-2990.2008.00977.x. Neuropathol Appl Neurobiol. 2009. PMID: 19284481 - Amplified genes in human gliomas.
Collins VP. Collins VP. Semin Cancer Biol. 1993 Feb;4(1):27-32. Semin Cancer Biol. 1993. PMID: 8448375 Review. - Molecular genetic analysis of deep-seated glioblastomas.
Hayashi Y, Yamashita J, Watanabe T. Hayashi Y, et al. Cancer Genet Cytogenet. 2004 Aug;153(1):64-8. doi: 10.1016/j.cancergencyto.2003.12.010. Cancer Genet Cytogenet. 2004. PMID: 15325097 Review.
Cited by
- Multimodal scanning of genetic variants with base and prime editing.
Belli O, Karava K, Farouni R, Platt RJ. Belli O, et al. Nat Biotechnol. 2024 Nov 12. doi: 10.1038/s41587-024-02439-1. Online ahead of print. Nat Biotechnol. 2024. PMID: 39533106 - The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma.
Wu Q, Berglund AE, Macaulay RJ, Etame AB. Wu Q, et al. Cells. 2024 May 30;13(11):942. doi: 10.3390/cells13110942. Cells. 2024. PMID: 38891074 Free PMC article. Review. - Artificial neural network identified a 20-gene panel in predicting immunotherapy response and survival benefits after anti-PD1/PD-L1 treatment in glioblastoma patients.
Wang Y, Wang Z, Guo X, Cao Y, Xing H, Wang Y, Xing B, Wang Y, Yao Y, Ma W. Wang Y, et al. Cancer Med. 2024 May;13(9):e7218. doi: 10.1002/cam4.7218. Cancer Med. 2024. PMID: 38733169 Free PMC article. - Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, Pineda B, Gutiérrez-Arroyo JL, Loras A, Gonzalez-Bonet LG, Martinez-Cadenas C, Estrela JM, Marqués-Torrejón MÁ. Obrador E, et al. Int J Mol Sci. 2024 Feb 21;25(5):2529. doi: 10.3390/ijms25052529. Int J Mol Sci. 2024. PMID: 38473776 Free PMC article. Review. - Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors.
Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen H. Zheng L, et al. Cancers (Basel). 2023 Dec 19;16(1):6. doi: 10.3390/cancers16010006. Cancers (Basel). 2023. PMID: 38201434 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous